Cardinal Health (CAH) Q1 2027 Earnings Call Transcript
Cardinal Health (CAH) reported Q1 2027 revenue of $67.5B (+5% YoY) and raised fiscal 2027 EPS guidance to $12.80-$13.00. The company renewed its contract with CVS Health (CVS) through 2032, securing long-term stability. Pharma segment revenue grew 6%, while GMPD revenue was flat. Profit increased across all segments, with operating income reaching $1B. The company repurchased $500M in shares and maintained strong cash flow.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift reinforce the company's operational leverage and may trigger buying interest in the stock.
Market read
Strong earnings and guidance raise make CAH a near‑term buying candidate, with potential spillover to the broader healthcare distribution sector.
What to watch
Potential headwinds from IRA WAC reductions and commodity cost pressures could temper long‑term upside.
Background
Cardinal Health's Q1 2027 earnings call disclosed a 5% revenue increase to $67.5 bn, 28% EPS growth, and a $500 m share‑repurchase program, culminating in an EPS guidance raise.
Ticker impact
Cardinal Health raised its FY 2027 EPS guidance to $12.80‑$13.00, up from $12.40‑$12.60, and reported Q1 earnings beat.
likely upward pressure as investors price in higher earnings expectations
The new EPS range exceeds prior guidance by 3‑4%, indicating material improvement in profitability.
Market effects
Healthcare distribution and pharma services sector may see broader optimism as Cardinal Health's guidance lift suggests demand strength.
U.S. large‑cap healthcare stocks could benefit from the upbeat outlook.
Limited to U.S. markets; no immediate global macro effect.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back on profit‑taking.
Key entities
- CompanyCardinal Health
U.S. healthcare services and distribution firm (ticker CAH).
